Arachidonic acid metabolism in human prostate cancer

Yang,Peiying; Cartwright,Carrie  A.; Li,Jin; Wen,Sijin; Prokhorova,Ina  N.; Shureiqi,Imad; Troncoso,Patricia; Navone,Nora  M.; Newman,Robert  A.; Kim,Jeri

doi:10.3892/ijo.2012.1588

Arachidonic acid metabolism in human prostate cancer

Authors:
- Peiying Yang
- Carrie A. Cartwright
- Jin Li
- Sijin Wen
- Ina N. Prokhorova
- Imad Shureiqi
- Patricia Troncoso
- Nora M. Navone
- Robert A. Newman
- Jeri Kim
View Affiliations

Affiliations: Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Published online on: August 10, 2012 https://doi.org/10.3892/ijo.2012.1588
Pages: 1495-1503

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The arachidonic acid pathway is important in the development and progression of numerous malignant diseases, including prostate cancer. To more fully evaluate the role of individual cyclooxygenases (COXs), lipoxygenases (LOXs) and their metabolites in prostate cancer, we measured mRNA and protein levels of COXs and LOXs and their arachidonate metabolites in androgen-dependent (LNCaP) and androgen-independent (PC-3 and DU145) prostate cancer cell lines, bone metastasis-derived MDA PCa 2a and MDA PCa 2b cell lines and their corresponding xenograft models, as well as core biopsy specimens of primary prostate cancer and nonneoplastic prostate tissue taken ex vivo after prostatectomy. Relatively high levels of COX-2 mRNA and its product PGE2 were observed only in PC-3 cells and their xenografts. By contrast, levels of the exogenous 12-LOX product 12-HETE were consistently higher in MDA PCa 2b and PC-3 cells and their corresponding xenograft tissues than were those in LNCaP cells. More strikingly, the mean endogenous level of 12-HETE was significantly higher in the primary prostate cancers than in the nonneoplastic prostate tissue (0.094 vs. 0.010 ng/mg protein, respectively; p=0.019). Our results suggest that LOX metabolites such as 12-HETE are critical in prostate cancer progression and that the LOX pathway may be a target for treating and preventing prostate cancer.

View Figures

View References

1	Baade PD, Youlden DR and Krnjacki LJ: International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res. 53:171–184. 2009. View Article : Google Scholar : PubMed/NCBI
2	Coleman MP, Quaresma M, Berrino F, et al: Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 9:730–756. 2008. View Article : Google Scholar : PubMed/NCBI
3	Crowe FL, Key TJ, Appleby PN, et al: Dietary fat intake and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr. 87:1405–1413. 2008.
4	Bidoli E, Talamini R, Bosetti C, et al: Macronutrients, fatty acids, cholesterol and prostate cancer risk. Ann Oncol. 16:152–157. 2005. View Article : Google Scholar : PubMed/NCBI
5	Rose DP and Connolly JM: Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate. 18:243–254. 1991. View Article : Google Scholar : PubMed/NCBI
6	Pandalai PK, Pilat MJ, Yamazaki K, Naik H and Pienta KJ: The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth. Anticancer Res. 16:815–820. 1996.PubMed/NCBI
7	Chaudry AA, Wahle KW, McClinton S and Moffat LE: Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. Int J Cancer. 57:176–180. 1994. View Article : Google Scholar : PubMed/NCBI
8	Anderson KM, Wygodny JB, Ondrey F and Harris J: Human PC-3 prostate cell line DNA synthesis is suppressed by eicosatetraynoic acid, an in vitro inhibitor of arachidonic acid metabolism. Prostate. 12:3–12. 1988. View Article : Google Scholar : PubMed/NCBI
9	Berquin IM, Min Y, Wu R, et al: Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest. 117:1866–1875. 2007. View Article : Google Scholar : PubMed/NCBI
10	Higgs GA, Moncada S and Vane JR: Eicosanoids in inflammation. Ann Clin Res. 16:287–299. 1984.
11	Wallace JM: Nutritional and botanical modulation of the inflammatory cascade--eicosanoids, cyclooxygenases, and lipoxygenases--as an adjunct in cancer therapy. Integr Cancer Ther. 1:7–37. 2002.PubMed/NCBI
12	Hughes-Fulford M, Chen Y and Tjandrawinata RR: Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells. Carcinogenesis. 22:701–707. 2001. View Article : Google Scholar : PubMed/NCBI
13	Subbarayan V, Sabichi AL, Llansa N, Lippman SM and Menter DG: Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. Cancer Res. 61:2720–2726. 2001.PubMed/NCBI
14	Tang K and Honn KV: 12(S)-HETE in cancer metastasis. Adv Exp Med Biol. 447:181–191. 1999. View Article : Google Scholar : PubMed/NCBI
15	Yin B, Yang Y, Zhao Z, et al: Arachidonate 12-lipoxygenase may serve as a potential marker and therapeutic target for prostate cancer stem cells. Int J Oncol. 38:1041–1046. 2011.PubMed/NCBI
16	Ghosh J and Myers CE: Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA. 95:13182–13187. 1998. View Article : Google Scholar
17	Tang S, Bhatia B, Maldonado CJ, et al: Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells. J Biol Chem. 277:16189–16201. 2002. View Article : Google Scholar : PubMed/NCBI
18	Shureiqi I, Chen D, Lee JJ, et al: 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer Inst. 92:1136–1142. 2000. View Article : Google Scholar : PubMed/NCBI
19	Vanaja DK, Grossmann ME, Celis E and Young CY: Tumor prevention and antitumor immunity with heat shock protein 70 induced by 15-deoxy-delta12,14-prostaglandin J2 in transgenic adenocarcinoma of mouse prostate cells. Cancer Res. 60:4714–4718. 2000.
20	Wang MT, Honn KV and Nie D: Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev. 26:525–534. 2007. View Article : Google Scholar : PubMed/NCBI
21	Dassesse T, de Leval X, de Leval L, Pirotte B, Castronovo V and Waltregny D: Activation of the thromboxane A2 pathway in human prostate cancer correlates with tumor Gleason score and pathologic stage. Eur Urol. 50:1021–1031. 2006. View Article : Google Scholar : PubMed/NCBI
22	Nie D, Guo Y, Yang D, et al: Thromboxane A2 receptors in prostate carcinoma: expression and its role in regulating cell motility via small GTPase Rho. Cancer Res. 68:115–121. 2008. View Article : Google Scholar : PubMed/NCBI
23	Nie D, Che M, Zacharek A, et al: Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility. Am J Pathol. 164:429–439. 2004. View Article : Google Scholar : PubMed/NCBI
24	Wang X, Colby JK, Yang P, Fischer SM, Newman RA and Klein RD: The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue. Carcinogenesis. 29:120–128. 2008. View Article : Google Scholar : PubMed/NCBI
25	Shappell SB, Olson SJ, Hannah SE, et al: Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma. Cancer Res. 63:2256–2267. 2003.PubMed/NCBI
26	Shappell SB, Manning S, Boeglin WE, et al: Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia. 3:287–303. 2001. View Article : Google Scholar : PubMed/NCBI
27	Bhatia B, Maldonado CJ, Tang S, et al: Subcellular localization and tumor-suppressive functions of 15-lipoxygenase 2 (15-LOX2) and its splice variants. J Biol Chem. 278:25091–25100. 2003. View Article : Google Scholar : PubMed/NCBI
28	Navone NM, Olive M, Ozen M, et al: Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res. 3:2493–2500. 1997.PubMed/NCBI
29	Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e452001. View Article : Google Scholar : PubMed/NCBI
30	Shureiqi I, Zuo X, Broaddus R, et al: The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer. FASEB J. 21:743–753. 2007. View Article : Google Scholar : PubMed/NCBI
31	Kempen EC, Yang P, Felix E, Madden T and Newman RA: Simultaneous quantification of arachidonic acid metabolites in cultured tumor cells using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Anal Biochem. 297:183–190. 2001. View Article : Google Scholar
32	Yang P, Felix E, Madden T, Fischer SM and Newman RA: Quantitative high-performance liquid chromatography/electrospray ionization tandem mass spectrometric analysis of 2- and 3-series prostaglandins in cultured tumor cells. Anal Biochem. 308:168–177. 2002. View Article : Google Scholar
33	Yang P, Chan D, Felix E, et al: Determination of endogenous tissue inflammation profiles by LC/MS/MS: COX- and LOX-derived bioactive lipids. Prostaglandins Leukot Essent Fatty Acids. 75:385–395. 2006. View Article : Google Scholar : PubMed/NCBI
34	Yang P, Collin P, Madden T, et al: Inhibition of proliferation of PC3 cells by the branched-chain fatty acid, 12-methyltetradecanoic acid, is associated with inhibition of 5-lipoxygenase. Prostate. 55:281–291. 2003. View Article : Google Scholar : PubMed/NCBI
35	Dahiya R, Yoon WH, Boyle B, Schoenberg S, Yen TS and Narayan P: Biochemical, cytogenetic, and morphological characteristics of human primary and metastatic prostate cancer cell lines. Biochem Int. 27:567–577. 1992.PubMed/NCBI
36	Wang Y, Corr JG, Thaler HT, Tao Y, Fair WR and Heston WD: Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst. 87:1456–1462. 1995. View Article : Google Scholar : PubMed/NCBI
37	Angelucci A, Garofalo S, Speca S, et al: Arachidonic acid modulates the crosstalk between prostate carcinoma and bone stromal cells. Endocr Relat Cancer. 15:91–100. 2008. View Article : Google Scholar : PubMed/NCBI
38	Zha S, Gage WR, Sauvageot J, et al: Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res. 61:8617–8623. 2001.PubMed/NCBI
39	Kirschenbaum A, Klausner AP, Lee R, et al: Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology. 56:671–676. 2000. View Article : Google Scholar : PubMed/NCBI
40	Larre S, Tran N, Fan C, et al: PGE2 and LTB4 tissue levels in benign and cancerous prostates. Prostaglandins Other Lipid Mediat. 87:14–19. 2008. View Article : Google Scholar : PubMed/NCBI
41	Wang H, Wang X, Zeng A and Yang K: Effects of coherence on anisotropic electromagnetic Gaussian-Schell model beams on propagation. Opt Lett. 32:2215–2217. 2007. View Article : Google Scholar : PubMed/NCBI
42	Gao LJ, Wang XF, Yang HY, Gao XZ, Lu YC and Cui ZJ: Effects of a lactic acid bacteria community SFC-2 treated on rice straw. Huan Jing Ke Xue. 28:1392–1396. 2007.(In Chinese).
43	Timar J, Raso E, Dome B, et al: Expression, subcellular localization and putative function of platelet-type 12-lipoxygenase in human prostate cancer cell lines of different metastatic potential. Int J Cancer. 87:37–43. 2000. View Article : Google Scholar
44	Nie D, Hillman GG, Geddes T, et al: Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Res. 58:4047–4051. 1998.PubMed/NCBI
45	Kelavkar UP, Harya NS, Hutzley J, et al: DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation. Prostaglandins Other Lipid Mediat. 82:185–197. 2007. View Article : Google Scholar
46	Kelavkar UP, Parwani AV, Shappell SB and Martin WD: Conditional expression of human 15-lipoxygenase-1 in mouse prostate induces prostatic intraepithelial neoplasia: the FLiMP mouse model. Neoplasia. 8:510–522. 2006. View Article : Google Scholar : PubMed/NCBI
47	Shappell SB, Boeglin WE, Olson SJ, Kasper S and Brash AR: 15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am J Pathol. 155:235–245. 1999. View Article : Google Scholar : PubMed/NCBI
48	Gonzalez AL, Roberts RL, Massion PP, Olson SJ, Shyr Y and Shappell SB: 15-Lipoxygenase-2 expression in benign and neoplastic lung: an immunohistochemical study and correlation with tumor grade and proliferation. Hum Pathol. 35:840–849. 2004. View Article : Google Scholar : PubMed/NCBI